{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:08:58Z","timestamp":1791209338730,"version":"4.1.0"},"reference-count":51,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1205803"],"award-info":[{"award-number":["2022YFA1205803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["CIFMS 2021-I2M-1-026"],"award-info":[{"award-number":["CIFMS 2021-I2M-1-026"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7244372"],"award-info":[{"award-number":["7244372"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB36000000"],"award-info":[{"award-number":["XDB36000000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gemcitabine (GEM) is a first-line therapeutic option for pancreatic cancer; however, it has low efficacy due to rapidly developed drug resistance and severe dose-limiting myelosuppression. To enhance its therapeutic effect, this study developed a novel peptide\u2212drug conjugate using a CXCR4 antagonistic peptide as the targeting head and gemcitabine as the drug payload, based on the characteristics of pancreatic tumor cells highly expressing CXCR4 that mediates immunosuppression and tumor progression through interaction with its specific ligand CXCL12. The therapeutic effect of the conjugate (P12-GEM) was investigated using pancreatic ductal adenocarcinoma cell lines and an orthotopic pancreatic cancer mouse model. Its myelosuppressive effect was assessed from the perspective of hematological toxicity profiles. The results showed that P12-GEM maintained a cell-killing capability comparable to that of GEM while effectively inhibiting the phosphorylation of Erk and P38, thereby reducing CXCL12-mediated tumor cell migration and adhesion to stromal cells. In a tumor-bearing mouse model, P12-GEM demonstrated superior antitumor efficacy compared to GEM and significantly extended animal survival. Moreover, P12-GEM reduced the proportion of tumor-associated macrophages and increased the infiltration of CD8+ T cells in the tumor microenvironment without reducing platelet and white blood cell counts in the peripheral blood. In summary, P12-GEM possesses dual functions of CXCR4 antagonism and tumor cell killing, contributing to reversal of the immunosuppressive microenvironment and alleviation of myelotoxicity.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00292","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:34:46Z","timestamp":1788168886000},"page":"4843-4856","source":"Crossref","is-referenced-by-count":0,"title":["A Dual-Action CXCR4-Targeted Peptide\u2212Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer"],"prefix":"10.1021","volume":"23","author":[{"given":"Ke","family":"Zhu","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-3139","authenticated-orcid":true,"given":"Tao","family":"Wen","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-6316","authenticated-orcid":true,"given":"Xiaocui","family":"Fang","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences , , ,","place":["Beijing, China, 100049"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-5509","authenticated-orcid":true,"given":"Yanlian","family":"Yang","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences , , ,","place":["Beijing, China, 100049"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]},{"name":"Chinese Academy of Medical Science & Peking Union Medical College , , ,","place":["Tianjin, China, 301600"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]},{"name":"Chinese Academy of Medical Science & Peking Union Medical College , , ,","place":["Tianjin, China, 301600"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-9089","authenticated-orcid":true,"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences , , ,","place":["Beijing, China, 100049"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-9048","authenticated-orcid":true,"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, China, 100005"]},{"name":"Chinese Academy of Medical Science & Peking Union Medical College , , ,","place":["Tianjin, China, 301600"]},{"name":"Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations , ,","place":["Beijing, China, 102600"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"1","key":"2026100509323237500_cit1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"10485","key":"2026100509323237500_cit2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"2026100509323237500_cit3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"11","key":"2026100509323237500_cit4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"2026100509323237500_cit5","unstructured":"National Comprehensive Cancer Network (NCCN)\n          . NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2025. Published February 3."},{"issue":"5","key":"2026100509323237500_cit6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/op.24.00279","article-title":"Novel therapies for pancreatic cancer","volume":"21","author":"Chung","year":"2025","journal-title":"JCO Oncol. Pract."},{"issue":"6","key":"2026100509323237500_cit7","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/jco.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"2026100509323237500_cit8","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/jco.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"2026100509323237500_cit9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1248\/bpb.34.1765","article-title":"The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients","volume":"34","author":"Iwata","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"2026100509323237500_cit10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.pharmthera.2017.05.012","article-title":"Emerging roles of the CXCL12\/CXCR4 axis in pancreatic cancer progression and therapy","volume":"179","author":"Sleightholm","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"2026100509323237500_cit11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/sj.bjc.6605968","article-title":"CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy","volume":"103","author":"Singh","year":"2010","journal-title":"Br. J. Cancer"},{"key":"2026100509323237500_cit12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12885-016-2340-z","article-title":"Enhancement of the CXCL12\/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists","volume":"16","author":"Morimoto","year":"2016","journal-title":"BMC Cancer"},{"issue":"29","key":"2026100509323237500_cit13","doi-asserted-by":"publisher","first-page":"21197","DOI":"10.1074\/jbc.M113.484576","article-title":"An undesired effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4","volume":"288","author":"Arora","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2026100509323237500_cit14","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3389\/fonc.2019.01359","article-title":"Ping-Pong-Tumor and Host in Pancreatic Cancer Progression","volume":"9","author":"Mu","year":"2019","journal-title":"Front. Oncol."},{"key":"2026100509323237500_cit15","doi-asserted-by":"publisher","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"2026100509323237500_cit16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"issue":"2","key":"2026100509323237500_cit17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41416-021-01315-y","article-title":"AMD3100\/ Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells","volume":"125","author":"Fearon","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"2026100509323237500_cit18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40364-025-00778-y","article-title":"Targeting the chemokine receptor CXCR4 for cancer therapies","volume":"13","author":"Rueda","year":"2025","journal-title":"Biomark. Res."},{"issue":"13","key":"2026100509323237500_cit19","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1158\/1078-0432.ccr-13-2686","article-title":"A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer","volume":"20","author":"Galsky","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"2026100509323237500_cit20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/s1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"Pernas","year":"2018","journal-title":"Lancet Oncol."},{"issue":"18","key":"2026100509323237500_cit21","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.ccr-21-0929","article-title":"Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026100509323237500_cit22","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1039\/d5md00488h","article-title":"Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine","volume":"16","author":"Huang","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"22","key":"2026100509323237500_cit23","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.1158\/0008-5472.can-04-1343","article-title":"Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4","volume":"64","author":"Marchesi","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"2026100509323237500_cit24","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.7314\/apjcp.2013.14.9.5403","article-title":"CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells","volume":"14","author":"Shen","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2026100509323237500_cit25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12013-017-0789-2","article-title":"IDH-Inhibiting Small Molecule DTDQ Inhibits Migration and Invasion of A549 Human Non-Small-Cell Lung Cancer Cells via Sequential Inactivation Of ERK and P38 Signaling Pathways","volume":"76","author":"Park","year":"2018","journal-title":"Cell Biochem. Biophys."},{"key":"2026100509323237500_cit26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.canlet.2004.04.035","article-title":"CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma","volume":"214","author":"Samara","year":"2004","journal-title":"Cancer Lett."},{"key":"2026100509323237500_cit27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-cancerbio-061421-035400","article-title":"Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer","volume":"7","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"3","key":"2026100509323237500_cit28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00006676-200410000-00004","article-title":"Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity","volume":"29","author":"Loukopoulos","year":"2004","journal-title":"Pancreas"},{"issue":"2","key":"2026100509323237500_cit29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.cd-22-0876","article-title":"Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer","volume":"13","author":"Falcomata\u0300","year":"2023","journal-title":"Cancer Discovery"},{"issue":"2","key":"2026100509323237500_cit30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1021\/mp300370t","article-title":"Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications","volume":"10","author":"Moysan","year":"2013","journal-title":"Mol. Pharmaceutics"},{"issue":"13","key":"2026100509323237500_cit31","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.bmcl.2017.04.086","article-title":"Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides","volume":"27","author":"Vale","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"98","key":"2026100509323237500_cit32","doi-asserted-by":"publisher","first-page":"17435","DOI":"10.1039\/c5cc06654a","article-title":"The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells","volume":"51","author":"Han","year":"2015","journal-title":"Chem. Commun."},{"issue":"4","key":"2026100509323237500_cit33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41419-023-05820-1","article-title":"Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Cell Death Dis."},{"issue":"7","key":"2026100509323237500_cit34","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1158\/1078-0432.ccr-20-3210","article-title":"A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer","volume":"27","author":"Cazes","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"38","key":"2026100509323237500_cit35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507118","article-title":"Cascade-Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci."},{"issue":"12","key":"2026100509323237500_cit36","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27231","article-title":"Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase","volume":"2","author":"Amit","year":"2013","journal-title":"OncoImmunology"},{"issue":"29","key":"2026100509323237500_cit37","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1038\/onc.2013.357","article-title":"Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase","volume":"33","author":"Weizman","year":"2014","journal-title":"Oncogene"},{"key":"2026100509323237500_cit38","doi-asserted-by":"publisher","first-page":"104458","DOI":"10.1016\/j.cellimm.2021.104458","article-title":"SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4\/CXCL12 axis","volume":"371","author":"Fang","year":"2022","journal-title":"Cell. Immunol."},{"issue":"5","key":"2026100509323237500_cit39","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1096\/fj.201802067rr","article-title":"Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment","volume":"33","author":"Zeng","year":"2019","journal-title":"FASEB J."},{"issue":"8","key":"2026100509323237500_cit40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41565-025-01924-1","article-title":"A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer","volume":"20","author":"Zhao","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"2026100509323237500_cit41","doi-asserted-by":"publisher","first-page":"171111","DOI":"10.1016\/j.peptides.2023.171111","article-title":"EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models","volume":"175","author":"Sagini","year":"2024","journal-title":"Peptides"},{"issue":"1","key":"2026100509323237500_cit42","doi-asserted-by":"publisher","first-page":"2543614","DOI":"10.1080\/2162402x.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"OncoImmunology"},{"issue":"50","key":"2026100509323237500_cit43","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"2026100509323237500_cit44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"2026100509323237500_cit45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"2026100509323237500_cit46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13402-026-01165-x","article-title":"CXCL12 derived from cancer-associated fibroblasts mediates dysfunctional intratumoral adaptive immunity in diabetic pancreatic adenocarcinoma","volume":"49","author":"Wang","year":"2026","journal-title":"Cell. Oncol."},{"issue":"5","key":"2026100509323237500_cit47","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1021\/acs.molpharmaceut.6b00929","article-title":"Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice","volume":"14","author":"Kattel","year":"2017","journal-title":"Mol. Pharmaceutics"},{"issue":"637","key":"2026100509323237500_cit48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc1600","article-title":"Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice","volume":"14","author":"Selvanesan","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"2026100509323237500_cit49","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001273r","article-title":"Polyfunctionality of the CXCR4\/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune-mediated diseases","volume":"35","author":"Britton","year":"2021","journal-title":"FASEB J."},{"key":"2026100509323237500_cit50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.biocel.2017.12.018","article-title":"The good and bad faces of the CXCR4 chemokine receptor","volume":"95","author":"Teixido\u0301","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"8","key":"2026100509323237500_cit51","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.20041385","article-title":"Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist","volume":"201","author":"Broxmeyer","year":"2005","journal-title":"J. Exp. Med."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00292","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4843\/67352724\/mp6c00292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4843\/67352724\/mp6c00292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:15Z","timestamp":1791208155000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/4843\/5324369\/A-Dual-Action-CXCR4-Targeted-Peptide-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00292","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}